A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization

Anand D Jeyasekharan1, Yang Liu1, Hiroyoshi Hattori1,3, Venkat Pisupati1,3, Asta Bjork Jonsdottir1, Eeson Rajendra1, Miyoung Lee1, Elayanambi Sundaramoorthy1, Simon Schlachter2, Clemens F Kaminski2, Yaara Rosenfeld1, Ko Sato1, Jane Savill1, Nabieh Ayoub1 & Ashok R Venkitaraman1

Germline missense mutations affecting a single BRCA2 allele predispose humans to cancer. Here we identify a protein-targeting mechanism that is disrupted by the cancer-associated mutation, BRCA2D2723H, and that controls the nuclear localization of BRCA2 and its cargo, the recombinase enzyme RAD51. A nuclear export signal (NES) in BRCA2 is masked by its interaction with a partner protein, DSS1, such that point mutations impairing BRCA2-DSS1 binding render BRCA2 cytoplasmic. In turn, cytoplasmic mislocalization of mutant BRCA2 inhibits the nuclear retention of RAD51 by exposing a similar NES in RAD51 that is usually obscured by the BRCA2-RAD51 interaction. Thus, a series of NES-masking interactions localizes BRCA2 and RAD51 in the nucleus. Notably, BRCA2D2723H decreases RAD51 nuclear retention even when wild-type BRCA2 is also present. Our findings suggest a mechanism for the regulation of the nucleocytoplasmic distribution of BRCA2 and RAD51 and its impairment by a heterozygous disease-associated mutation.

RESULTS

DSS1 binding to BRCA2 is critical for nuclear localization
Cancer-associated missense mutations in human BRCA2 occur frequently in the region that spans residues 2500–2850 (ref. 17), which mediates the interaction (Supplementary Fig. 1a) of BRCA2 with the small (70-residue), acidic protein DSS1 (refs. 18,19). One of these mutations, BRCA2D2723H, which alters a single aspartic acid residue to histidine, has been reported >30 times in the Breast Cancer Information Core database (http://research.nhgri.nih.gov/bic/). Evidence from linkage analysis of human kindreds16 and functional studies on mouse embryonic stem (ES) cells has suggested that the inheritance of BRCA2D2723H is functionally deleterious20. Because the BRCA2D2723H mutation affects a key conserved residue (Supplementary Fig. 1a) that directly contacts DSS1 (ref. 19), we first determined whether it affects the BRCA2-DSS1 interaction. We generated a fragment of BRCA2 spanning the entire DSS1-binding domain (DBD) across residues 2461–2975 fused to ‘super’ YFP (sYFP) plus a nuclear localization signal (NLS) and coexpressed it in human 293T cells with an mCherry-tagged form of full-length DSS1. The sYFP-DBD fragment is >70 kDa long and therefore requires a heterologous NLS to induce nuclear localization. Although the WT form of NLS-sYFP-DBD coimmunoprecipitated with mCherry-DSS1 (Fig. 1a), the BRCA2D2723H mutant did not, despite having higher expression levels. Similarly, a mutant form of the DBD (BRCA2W2725A) in which an evolutionarily conserved tryptophan residue at position 2725 that has been implicated in DSS1 binding21 is altered to alanine immunoprecipitated poorly with mCherry-DSS1.

Inherited germline mutations in a single copy of the BRCA2 tumor-suppressor gene predispose to breast, ovarian, pancreatic and other cancers1. Somatic loss of the second allele may occur in tumors that develop in mutation carriers2,3, as with other tumor-suppressor genes4, but loss of this second allele is not always essential for tumorigenesis5. Much evidence has suggested that BRCA2 controls the accumulation of the RAD51 recombinase enzyme at sites of DNA breakage in the nucleus8,9, nucleates RAD51 filament formation at single-stranded DNA (ssDNA)–double-stranded DNA (dsDNA) junctions10 and promotes RAD51 binding on ssDNA while inhibiting dsDNA binding11–15. However, defective HR typically occurs in cells lacking both BRCA2 alleles7, and so it remains unclear how heterozygous cancer-associated mutations may compromise the function of BRCA2.

To address this issue, we investigated the cellular effects of a common cancer-associated BRCA2 missense mutation (BRCA2D2723H), in which Asp2723 is replaced by histidine16. Remarkably, our studies reveal an unreported mechanism wherein the localization of BRCA2 and RAD51 to the cell nucleus is governed by the masking of NESs by protein-protein interactions. The BRCA2D2723H mutant impairs this mechanism, triggering decreased nuclear accumulation of RAD51 even when wild-type (WT) BRCA2 is also present, which contributes to its deleterious effects in the heterozygous state. Thus, our results link the nucleocytoplasmic translocation of the BRCA2 tumor suppressor to the cellular mechanisms of disease after its germline inactivation.

1The Medical Research Council (MRC) Cancer Unit, University of Cambridge, Hutchison–MRC Research Centre, Cambridge, UK. 2Department of Chemical Engineering, University of Cambridge, Cambridge, UK. 3These authors contributed equally to this work. Correspondence should be addressed to A.R.V. (arv22@cam.ac.uk).

Received 6 May; accepted 25 July; published online 8 September 2013; doi:10.1038/nsmb.2666
Figure 1 DSS1 binding correlates with localization of BRCA2. (a) Immunoprecipitation of sYFP-tagged NLS-DDB fragments with mCherry-DSS1 in 293T cells using an anti-GFP polyclonal serum. Left, results from whole-cell lysate (10% of the input); right, results from the immunoprecipitate. Transfection of free sYFP with mCherry-DSS1 served as the negative control for the immunoprecipitation (IP). Endogenous BRCA2 was the loading control for the western blot (WB). The uncropped blots are shown in Supplementary Figure 1d. (b) Dot plot of the mean sYFP lifetime per cell from a FRET-FLIM experiment with NLS-sYFP-DDB and mCherry-DSS1. Each dot represents a single cell; the horizontal lines and error bars represent the means and 95% confidence intervals, respectively, for the population studied in the experiment. U2OS cells co-transfected with the indicated constructs were analyzed by TCSPC. The P values shown were calculated by two-tailed Student’s t test. n = 35 cells for WT, WT + DSS1 and D2723H + DSS1; n = 9 cells for W2725A + DSS1. (c) Representative immunofluorescent confocal micrographs of 293T cells nucleofected with Flag-tagged full-length versions of human (hs) WT BRCA2, BRCA2D2723H or BRCA2W2725A. Red indicates DNA, cyan indicates BRCA2 (detected by anti-Flag) and purple indicates endogenous DSS1 (detected by anti-DSS1).

Measurement of fluorescence resonance energy transfer (FRET) (Supplementary Fig. 1b), a near-field coupling effect, reports on specific intermolecular interactions when the interacting fluorophores are less than ~5 nm apart. sYFP and mCherry are an optimized FRET pair, with a Förster radius of ~5 nm, and thus exhibit an enhanced FRET efficiency compared to traditional blue-shifted fluorophore pairs. We used fluorescence lifetime imaging microscopy (FLIM) to measure FRET on the donor sYFP molecule, which has a fluorescence lifetime that shows monoexponential decay (Supplementary Fig. 1c). Co-transfection of mCherry-DSS1 with NLS-sYFP-DDB caused a significant decrease in the lifetime of sYFP from 3,100 to 2,750 ps on average, as evidenced by time-correlated single photon counting (TCSPC), which is suggestive of FRET through the direct interaction of these molecules (Fig. 1b and Supplementary Fig. 1d). In contrast, the lifetime of the NLS-sYFP-tagged BRCA2D2723H and BRCA2W2725A mutants remained close to 3,000 ps, confirming that the mutations inhibit the interaction of the BRCA2-DDB with DSS1 directly (Fig. 1b). Human BRCA2 normally localizes to the cell nucleus through tandem nuclear localization signals (NLSs) at its extreme C terminus. In contrast, full-length BRCA2 harboring the D2723H mutation mislocalized predominantly to the cytoplasm in transfected cells (Fig. 1c), as has been shown previously. Notably, BRCA2W2725A similarly mislocalized (Fig. 1c), suggesting a correlation between the loss of DSS1 binding and cytoplasmic mislocalization.

DSS1 masks a nuclear exclusion sequence in BRCA2

Neither the D2723H nor the W2725A mutation is predicted to alter the canonical NLSs positioned in exon 27 of BRCA2 (ref. 24). This prompted us to survey BRCA2 for NESs using the NetNES program, which employs neural networks to predict consensus motifs fitting the pattern $\phi X_1-\phi X_2-\phi Y_2$, where $\phi$ is a hydrophobic amino acid (methionine, phenylalanine, isoleucine, valine or leucine) and X is any amino acid. We detected four such potential NES motifs in the DSS1-binding region of BRCA2 (Supplementary Fig. 2a). One motif (residues 2682–2698, encoded in exon 18 of BRCA2) showed strong evolutionary conservation, particularly of the critical hydrophobic residues (Fig. 2a). When fused to sYFP, this motif induced nuclear exclusion, which is in contrast to the effects of a control BRCA2-derived peptide of similar size (Fig. 2b); these results substantiate the NES function of the motif.

The cytoplasmic mislocalization of BRCA2 mutants carrying alterations that affect DSS1 binding, but not intrinsic NLS or NES motifs, raises the possibility that the BRCA2-DSS1 interaction masks an NES of BRCA2. Consistent with this idea, the structure of the BRCA2-DSS1 complex suggests that the residues that are critical for binding to exportins in the potential NES spanning residues 2682–2698 in BRCA2 are obscured by DSS1 (Fig. 2c). Moreover, overexpression of DSS1 in cells expressing WT forms of either NLS-sYFP-DDB or full-length BRCA2 enhanced nuclear localization, whereas the BRCA2D2723H and BRCA2W2725A mutants were not similarly affected (Supplementary Fig. 2b–d). Together these findings support a model wherein the binding of DSS1 to BRCA2 is essential for its nuclear retention through the masking of an NES within the DDB.

BRCA2 masks a nuclear exclusion sequence in RAD51

The RAD51 recombinase, a 37-kDa protein that is central to DNA repair by HR, binds directly to the BRC repeats of BRCA2 (refs. 6, 28), creating an interaction that is essential for the efficient completion of recombination reactions. Eight BRC repeats are present in human BRCA2, and the structural basis of their interaction with RAD51 has been characterized by crystallography and structure-function analyses in mammalian cells. Notably, a NetNES analysis of human RAD51 identified a putative NES spanning residues 245–260 (Fig. 3a) that is strongly conserved across species (Fig. 3b). This NES lies within a recently identified binding site for the BRC repeats of BRCA2 (ref. 29), and an examination of the crystal structure revealed that key exportin-binding residues within this RAD51 NES are probably masked when the protein is bound to BRCA2 (Fig. 3c). The RAD51 NES was sufficient to exclude sYFP from the nucleus when fused to the fluorophore (Fig. 3d). Mutation of the residues Ser208 and Ala209 in RAD51 has been reported to abolish its binding to the BRC repeats in BRCA2 but not its ability to oligomerize.
This mutant localized to the cytoplasm when expressed in DT40 cells lacking endogenous RAD51 (Fig. 3e). These observations not only confirm that the nuclear retention of RAD51 requires binding to BRCA2 but also corroborate that a RAD51 NES is masked by interaction with the BRC repeats of BRCA2.

**In vitro interaction of CRM1 with NESs in BRCA2 and RAD51**

We demonstrated that putative NESs identified in the DSS1-binding domain of BRCA2 and the BRCA2-binding region of RAD51 share the expected consensus characteristics and can direct the nuclear exclusion of sYFP when fused to this heterologous protein. However, leucine residues in NES-like motifs frequently contribute to the buried hydrophobic cores of protein folds and may therefore be inaccessible for interaction with the nuclear exportin CRM1 in their native context. To address this issue, we tested the ability of glutathione S-transferase (GST)-tagged forms of the NES-containing domains of BRCA2 and RAD51 to bind in vitro to recombinant CRM1 in the presence of an active GTP-bound Q69L form of the essential cofactor Ran under the experimental conditions described previously. We found that a GST-tagged recombinant protein encoding the DBD region of BRCA2 bound to recombinant CRM1 in the presence of...
Figure 4 CRM1 binding to NESs in BRCA2 or RAD51 is masked by DSS1 or BRCA4, respectively. (a) Immunoblots of GST pulldown assays assessing the binding of CRM1 to GST-DBD (lanes 3 and 4) and GST-DBD2723H (lanes 5 and 6) immobilized on a glutathione-Sepharose matrix in the absence (lanes 3 and 5) or presence (lanes 4 and 6) of DSS1 at a five-fold molar excess. (b) Representative titration (of three total replicates) with GST as a specificity control, from which the molar excess of BRC4 peptide used in total replicates) with GST as a specificity control, from which the molar excess of DSS1 used in a was optimized. (c) Immunoblots of GST pulldown assays assessing binding of CRM1 to GST-RAD51F86E (lanes 3 and 4) and GST-RAD51-SAM (lanes 5 and 6) immobilized on a glutathione-Sepharose matrix in the absence (lanes 3 and 5) or presence of (lanes 4 and 6) of BRC4 peptide at a six-fold molar excess. (d) Representative titration (of three total replicates) with GST as a specificity control, from which the molar excess of BRC4 peptide used in c was optimized. Proteins were visualized with antibodies to histidine or GST. CRM1 protein was tagged with histidine (uncropped blots are shown in Supplementary Fig. 8).

In addition, we found biochemical evidence that RAD51 contains CRM1-binding NESs that are masked by interaction with the BRC4 region of BRCA2. In these experiments, we used the F86E form of RAD51, which we characterized previously to enable its purification without the spontaneous in vitro aggregation that is typical of recombinant WT RAD51 (refs. 28,34). A GST-tagged version of this protein bound to CRM1 in the presence of Ran-GTP (Fig. 4c). The addition of the BRC4 region of BRCA2 prevented CRM1 binding (Fig. 4c, compare lanes 3 and 4) in a dose-dependent manner (Fig. 4d). Notably, a mutant form of RAD51 (SAM208-210LEA, denoted here RAD51-SAM), which we have previously shown to be incapable of BRC4 binding, interacted constitutively with CRM1 regardless of whether BRC4 was present (Fig. 4d, lanes 5 and 6). Thus, these in vitro

Figure 5 RAD51 mislocalization by BRCA2 depletion or mutation. (a) Dot plot of the mean nucleocytoplasmic (nuc-cyto) difference of RAD51 per cell determined for a population of cells with or without exposure to BRCA2 siRNA. The insets show the algorithm used for determining the nucleocytoplasmic difference by automated microscopy. Left inset, the nucleus as defined by DAPI; middle inset, RAD51 staining; right inset, the algorithm for the nucleocytoplasmic intensity difference calculations (Online Methods) overlayed on the RAD51 image. AU, arbitrary units. Each circle represents the value from a single cell, the red lines indicate the means, and the error bars represent the 95% confidence intervals. n = 2,554 cells (control) or n = 2,478 cells (siBRCA2). (b) Cell fractionation experiment results from heterozygous mouse ES cells with western blotting for RAD51 to assess localization. MEK2 (which is predominantly cytoplasmic (cyto)) and SCC1 (which is predominantly nuclear (nuc)) served as loading controls as well as controls for the efficiency of fractionation. BAC(WT) indicates cells carrying a BAC expressing WT BRCA2; BAC(D2723H) indicates cells carrying a BAC expressing BRCA2D2723H. (c) Bar graph quantifying the results from three independent fractionation experiments. The nucleocytoplasmic intensity difference for RAD51 in each experiment was obtained by generating densitometric profiles for each band (identical exposure) using ImageJ and then subtracting the cytoplasmic value from the nuclear value. Lower (more negative) values indicate more cytoplasmic protein (n = 3 independent fractionation experiments; error bars, s.e.m.). (d,e) Cell fractionation experiment results from ES cells carrying BACs expressing either WT BRCA2 or BRCA2D2723H in the absence (d) or presence (e) of DNA damage induced by exposure to 100 ng ml⁻¹ of MMC for 20 h. SCC1 was used as a control for fractionation. One experiment representative of three independent repeats is shown. Uncropped blots are shown in Supplementary Figure 8.
results recapitulating exportin-cargo interactions using recombinant proteins provided strong biochemical evidence for a model wherein CRM1-dependent nuclear export—and its masking by protein-protein interactions—is a critical determinant of BRCA2 and RAD51 localization.

Our attempt at en bloc replacement of consensus hydrophobic residues within the proposed NESs (by substitution with alanine of Leu2686, Leu2688, Leu2696 and Ile2694 in the BRCA2 stretch from residues 2682–2698 and of Leu245, Leu249, Leu253 and Leu255 in the RAD51 stretch from residues 245–260) was beyond the scope of this work, as the BRCA2 and RAD51 domains encoding theputative NESs exhibited poor yield and solubility in bacterial expression. Moreover, further mutational analysis of the contributions made by residues located outside these motifs is difficult because the exact length and nature of the NES sequences that are required for CRM1 binding have been reported to be variable, as are the potential binding modes between CRM1 and its various substrates. Future structural work will be required to precisely define the residues contributing to NES activity.

A heterozygous D2723H mutation in BRCA2 mislocalizes RAD51

Our findings suggest that the nuclear retention of BRCA2 and RAD51 depends on NES-masking interactions between BRCA2 and DSS1 and between BRCA2 and RAD51. To investigate whether these interactions are interdependent, we first tested the effect of BRCA2 depletion on RAD51 localization using RNA interference (Fig. 5a). We used an automated microscopic assay in which the nucleocytoplasmic difference is calculated by subtracting the amount of RAD51 in a cytoplasmic ring surrounding the nucleus from the amount of RAD51 in a circular area within the nuclear boundary (as defined by DNA staining) (Fig. 5a, inset). We found that depletion of BRCA2 by RNA interference decreased the nuclear localization of RAD51 (Fig. 5a and Supplementary Fig. 3a–c), which is consistent with a role for BRCA2 in the nuclear retention of RAD51.

Because humans who inherit the D2723H mutation on a single allele of BRCA2 are predisposed to cancer, this raises the possibility that the mutant protein exerts a trans-dominant effect on RAD51 localization when in the heterozygous state. Accordingly, we examined RAD51 localization in mouse ES cells engineered to be heterozygous for the human BRCA2D2723H mutant in comparison to an appropriate WT control in an identical genetic background. In this system, one allele of mouse (mm) Brca2 was disrupted by gene targeting, and the cells were complemented with a bacterial artificial chromosome (BAC) containing a segment of human chromosome 13 encoding human (hs) BRCA2. This BAC has been reported to drive near-endogenous expression of BRCA2 and is sufficient to replace mmBrca2 function in these cells, as evidenced by the rescue of lethality when the second endogenous mmBrca2 allele is also disrupted. The total levels of BRCA2 and RAD51 expression were comparable in ES cells expressing either WT BRCA2 or BRCA2D2723H (Supplementary Fig. 4a,b).

We examined the distribution of RAD51 in these cells by biochemical fractionation and quantitative western blotting (Fig. 5b) because of technical difficulties in performing accurate microscopic analyses of protein localization in the ES cells. We observed an increase in the amount of cytoplasmic RAD51 in cells carrying a single allele of BRCA2D2723H, with a corresponding decrease in the nuclear levels of the protein (Fig. 5b,c) both in the absence (Fig. 5d) and presence (Fig. 5e) of DNA damage induced by mitomycin C (MMC). Mutant BRCA2D2723H expressed from the BAC in these cells was also predominantly cytoplasmic, unlike WT BRCA2 (ref. 20) (Fig. 5d,e).
Together these findings suggest a mechanism underlying the deleterious effects of the BRCA2 D2723H mutant when present in the heterozygous state and coexpressed with WT BRCA2.

**BRCA2 and DSS1 promote RAD51 nuclear enrichment**

There is evidence that RAD51 is enriched in the nucleus during the response to genotoxic lesions that are repaired by HR37,38. We characterized this effect further by analyzing the nucleocytoplasmic distribution of RAD51 after DNA damage in human cells using automated microscopy. Exposure to the DNA-damaging agents etoposide and MMC caused an increase in the relative amount of nuclear RAD51, as evidenced by changes in the nuclear-cytoplasmic difference of the average pixel intensities within the two regions (Fig. 6a and Supplementary Fig. 5). Moreover, genotoxins (e.g., MMC, carboplatin, the poly-(ADP-ribose) polymerase (PARP) inhibitor KU-0058948, hydroxyurea or aphidicolin) generating DNA lesions that are known to engage pathways for repair by HR enhanced the nuclear enrichment of RAD51 to a greater degree than other genotoxins (Fig. 6a). Depletion of ataxia telangiectasia mutated (ATM), ATM and 53 related (ATR) or CHK1, which are damage-response kinases39, diminished the nuclear enrichment of RAD51 after MMC exposure, confirming that this response depends on the cellular pathways that sense and signal DNA damage (Fig. 6c and Supplementary Fig. 6). Notably, depletion of BRCA2 or DSS1 also affected the nuclear enrichment of RAD51 after genotoxic stress (Fig. 6d and Supplementary Fig. 6). Using Flag-BRCA2–complemented EUFA423 cells (Supplementary Fig. 7), we showed that DNA damage also increases the levels of nuclear BRCA2, as measured with the Cellomics ArrayScan (Supplementary Fig. 7c), and depletion of DSS1 causes a decrease in nuclear Flag-BRCA2 levels (Supplementary Fig. 7d). Collectively these results suggest that the enhanced nuclear distribution of RAD51 is a DNA-damage response that is dependent on BRCA2 and DSS1 and that may be compromised by cancer-associated mutations that disrupt the DSS1-BRCA2 interaction.

**DISCUSSION**

The findings we report here suggest a new mechanism controlling the intracellular distribution of the RAD51 recombinase (Fig. 7) wherein NESs present in BRCA2 and its cargo, RAD51, must be masked by intracellular distribution of the RAD51 recombinase (Fig. 7d). Exposure to the DNA-damaging agents etoposide and MMC caused an increase in the relative amount of nuclear RAD51, as evidenced by changes in the nuclear-cytoplasmic difference of the average pixel intensities within the two regions (Fig. 6a and Supplementary Fig. 5). Moreover, genotoxins (e.g., MMC, carboplatin, the poly-(ADP-ribose) polymerase (PARP) inhibitor KU-0058948, hydroxyurea or aphidicolin) generating DNA lesions that are known to engage pathways for repair by HR enhanced the nuclear enrichment of RAD51 to a greater degree than other genotoxins (Fig. 6a). Depletion of ataxia telangiectasia mutated (ATM), ATM and 53 related (ATR) or CHK1, which are damage-response kinases39, diminished the nuclear enrichment of RAD51 after MMC exposure, confirming that this response depends on the cellular pathways that sense and signal DNA damage (Fig. 6c and Supplementary Fig. 6). Notably, depletion of BRCA2 or DSS1 also affected the nuclear enrichment of RAD51 after genotoxic stress (Fig. 6d and Supplementary Fig. 6). Using Flag-BRCA2–complemented EUFA423 cells (Supplementary Fig. 7), we showed that DNA damage also increases the levels of nuclear BRCA2, as measured with the Cellomics ArrayScan (Supplementary Fig. 7c), and depletion of DSS1 causes a decrease in nuclear Flag-BRCA2 levels (Supplementary Fig. 7d). Collectively these results suggest that the enhanced nuclear distribution of RAD51 is a DNA-damage response that is dependent on BRCA2 and DSS1 and that may be compromised by cancer-associated mutations that disrupt the DSS1-BRCA2 interaction.

**Figure 7** A hypothetical model for BRCA2 and RAD51 nuclear localization through masking of NESs. (a) The proposed mechanism wherein the nuclear retention of BRCA2 (red oblong shape) is allowed when its binding to DSS1 (black semicircle) obscures an NES motif. Nuclear transport (green arrow) is presumably directed by NLSs previously identified in the C-terminal region of BRCA2, which are not shown here. Dissociation of BRCA2 from DSS1 may permit nuclear export (blue arrow). (b) The proposed mechanism wherein the nuclear retention of RAD51 (orange circle) is allowed when its binding to the BRC repeats of BRCA2 obscures an NES motif. Nuclear transport (green arrow) of the BRCA2-RAD51 complex is presumably directed by the NLSs in BRCA2. In addition, cytosolic RAD51 may exist in an equilibrium (thin blue arrows) between free monomers and oligomers. Monomeric RAD51 is small enough to diffuse freely across the nuclear membrane (black arrows), whereas oligomers are not. Dissociation of RAD51 from BRCA2 may permit nuclear export (blue arrow). The net result of these different processes is to localize RAD51 predominantly in the nucleus. (c) How the processes shown in a and b may be affected by the BRCA2 D2723H mutation, which prevents DSS1 binding (black X). Mutant BRCA2 is exported from the nucleus (blue arrows), resulting in predominant cytoplasmic localization, and this is proposed to shift the balance toward cytoplasmic localization of RAD51, despite the presence of WT BRCA2.
monomers in which BRC binding obscures the NES, thus promoting nuclear retention. Depletion of DSS1, which not only binds to BRCA2 but is also a component of the 19S proteasome and RNA-processing complexes, impairs the assembly of RAD51 into foci at sites of DNA damage to mediate DNA HR. This effect has been ascribed previously to a direct function of the BRCA2-DSS1 complex in binding to ssDNA through the formation of oligonucleotide- and oligosaccharide-binding folds, which may not only localize RAD51 to these substrates but also displace the ssDNA-binding protein RPA. Our findings suggest that the localization may depend on the BRC repeat found in the nuclear localization of BRCA2 and, indirectly, RAD51. In this light, it is notable that mutant forms of BRCA2 in which the DSS1 binding domain has been entirely deleted are still capable of supporting HR. Moreover, DSS1 is apparently required for HR only when the DBD is present. These observations are consistent with our findings: DBD deletion presumably removes the strong NESs that we identified in this work, obviating the necessity for their masking by DSS1 and allowing mutant forms of BRCA2 lacking the DBD to at least partly function in the nucleus even without DSS1.

We surmise that DBD deletion and loss of DSS1 binding in human BRCA2 may lead to subtle defects in HR, which is reminiscent of the phenotypes observed in mutants of the BRCA2 homolog brh2 in the fungus *Ustilago maydis* that lack dss1 binding. Conversely, the NESs we identified in human BRCA2 are not well conserved in brh2 (Fig. 2a), raising the possibility that the mechanisms that regulate BRCA2 nuclear localization are not directly comparable between these species. However, *U. maydis* rad51 contains a conserved NES (Fig. 3a), suggesting that its localization may depend on the BRCA2 repeat found in brh2, whereas *Saccharomyces cerevisiae* Rad51 does not fit (Fig. 3a), which is consistent with the absence of a Brca2 homolog in yeast. Several lines of evidence have suggested that the DSS1-masked NESs we identified in BRCA2 are dominant in its function over other motifs such as NLSs within the protein that may control nuclear localization. For instance, the BRCA2-D2723H and BRCA2-W2725A point mutants, which both lack DSS1 binding to mask the NES, mislocalize to the cytosol, and the BRCA2-D2723H variant is embryonic lethal in mice when homozygous, suggesting that it is nonfunctional. Moreover, our findings suggest that these point mutations probably do not exert their effects simply through BRCA2 destabilization, as their protein expression is not markedly decreased. Instead, they speak to a critical role for the DSS1-TRCA2 interaction in the control of BRCA2-RAD51 localization. These findings raise questions regarding the expected clinical effects of the cancer-associated BRCA2-D2723H allele when expressed in the heterozygous state in germline mutation carriers. Although our findings suggest that BRCA2-D2723H heterozygosity may suffice to mislocalize RAD51, we are unaware that carriers of this mutation exhibit radiosensitivity or other clinical features that are associated with profound defects in DNA repair, which is consistent with the lack of radiosensitivity of cell lines carrying D2723H in vitro (Supplementary Fig. 4c). However, patients heterozygous for BRCA2-D2723H do appear to be at risk of developing early onset cancers, suggesting that this alteration causes a cumulative rather than an acute effect on genome stability, which acts over years to promote carcinogenesis. Indeed, BRCA2 is often cytotoxic in cancer cells, and mislocalization of RAD51 has been reported in both familial breast cancers and sporadic cases of prostate cancer.

Notably, our findings also indicate that alterations in the normal intracellular distribution of RAD51 may mark defects in the cellular response to DNA damage arising at several distinct steps (Fig. 6c, d).

We therefore suggest that quantitative measurement of the nucleocytoplasmic levels of RAD51 may serve as a surrogate marker for these defects, which may be of value in assessments of therapeutic responsiveness.

**METHODS**

Methods and any associated references are available in the online version of the paper.

**ACKNOWLEDGMENTS**

We acknowledge the generous gifts of WT and BRCA2-D2723H ES cells from S. Sharan (US National Institutes of Health) and sYFP DNA from T. Gadella (University of Amsterdam). We thank D. Görlich (Max Planck Institute) for generously providing constructs encoding RanQ69L and CRM1 and for consultation concerning assay conditions. We thank members of the Venkitaraman laboratory for technical assistance and constructive discussions and M. Goode for help with the feeder-free culture for ES cell cultures. A.D.J. was supported by a career development fellowship from the UK MRC Cancer Unit. Work in the laboratory of C.F.K. was funded by the UK Biosciences and Biotechnology Research Council, and work in the laboratory of A.R.V. was funded by the UK MRC.

**AUTHOR CONTRIBUTIONS**

A.D.J. and A.R.V. conceived the project. Experiments were performed by A.D.J., A.B.J., I.S. and M.L. (microscopy); Y.I. and M.L. (biochemistry); and A.D.J., H.H., P.B., A.B.J., E.S., Y.R., K.S. and N.A. (cell biology). Structural analysis was performed by E.R., and FRET-FLIM analysis was performed by S.S. and C.F.K. A.D.J. and A.R.V. wrote the manuscript.

**COMPETING FINANCIAL INTERESTS**

The authors declare no competing financial interests.

Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.

**REFERENCES**

1. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. *J. Natl. Cancer Inst.*, 1310–1316 (1999).
2. Collins, N. et al. Consistent loss of the wild-type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12–13. *Oncogene* 10, 1673–1675 (1995).
3. King, T.A. et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. *Ann. Surg. Oncol.* 14, 2510–2518 (2007).
4. Knudson, A.G. Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc. Natl. Acad. Sci. USA* 68, 820–823 (1971).
5. Skoulikis, F. et al. Germline BRCA2 heterozygosity promotes Kras-driven carcinogenesis in a murine model of familial pancreatic cancer. *Cell Cancer* 18, 499–509 (2010).
6. Xia, F. et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. *Proc. Natl. Acad. Sci. USA* 98, 8644–8649 (2001).
7. Moyerahan, M.E., Pierce, A.J. & Jasim, M. BRCA2 is required for homology-directed repair of chromosomal breaks. *Mol. Cell* 7, 263–272 (2001).
8. Chen, P.-L. et al. The BRCA repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. *Proc. Natl. Acad. Sci. USA* 95, 5287–5292 (1998).
9. Yuan, S.S. et al. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. *Cancer Res* 59, 3547–3551 (1999).
10. Yang, H., Li, Q., Fan, J., Holloman, W.K. & Pavletich, N.P. The BRCA2 homologue Brc2 nucleates RAD51 filament formation at a dsDNA-dsDNA junction. *Nature* 433, 653–657 (2005).
11. Thorslund, T. et al. The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. *Nat. Struct. Mol. Biol.* 17, 1263–1265 (2010).
12. Liu, J., Doty, T., Gibson, B. & Heyer, W.D. Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. *Nat. Struct. Mol. Biol.* 17, 1260–1262 (2010).
13. Jensen, R.B., Carreira, A. & Kowalczykowski, S.C. Purified human BRCA2 stimulates RAD51-mediated recombination. *Nature* 467, 678–683 (2010).
14. Carreira, A. et al. The BRCA repeats of BRCA2 modulate the DNA-binding selectivity of RAD51. *Cell* 136, 1032–1043 (2009).
15. Siwi, M.K. et al. The BRCA repeats of human BRCA2 differentially regulate RAD51 binding on single- versus double-stranded DNA to stimulate strand exchange. *Proc. Natl. Acad. Sci. USA* 106, 13254–13259 (2009).
16. Goldgár, D.E. et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. *Am. J. Hum. Genet.* 75, 535–544 (2004).
ARTICLES

17. Karchin, R., Agarwal, M., Sali, A., Couch, F., & Beattie, M.S. Classifying variants of undetermined significance in BRCA2 with protein likelihood ratios. Cancer Inform. 6, 203–216 (2008).

18. Marston, N.J. et al. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol. Cell Biol. 19, 4633–4642 (1999).

19. Yang, H. et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297, 1837–1848 (2002).

20. Kuznetsov, S.G., Liu, P. & Sharan, S.K. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat. Med. 14, 875–881 (2008).

21. Zhou, Q. et al. Dss1 interaction with Brh2 as a regulatory mechanism for recombinational repair. Mol. Cell Biol. 27, 2512–2526 (2007).

22. Jares-Erijman, E.A. & Jovin, T.M. FRET imaging. Nat. Biotechnol. 21, 1387–1395 (2003).

23. Goedhart, J., Vermeer, J.E.M., Adjobo-Hermans, M.J.W., van Weeren, L. & Gadella, T.W.J. Jr. Sensitive detection of p65 homodimers using red-shifted and fluorescent protein-based FRET couples. PLoS ONE 2, e1011 (2007).

24. Spain, B.H., Larson, C.J., Shihabuddin, L.S., Gage, F.H. & Verma, I.M. Truncated RAD51-BRCA2 complex. Mol. Cell Biol. 25, 2547–2557 (2005).

25. Wu, K. et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 65, 417–426 (2005).

26. la Cour, T. et al. Analysis and prediction of leucine-rich nuclear export signals. Protein Eng. Des. Sel. 17, 527–536 (2004).

27. Sonoda, E. et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J. 17, 598–608 (1998).

28. Pellegrini, L. et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420, 287–293 (2002).

29. Rajendra, E. & Venkitaraman, A.R. Two modules in the BRC repeat of BRCA2 mediate structural and functional interactions with the RAD51 recombinaise. Nucleic Acids Res. 38, 82–96 (2010).

30. Yu, D.S. et al. Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2. Mol. Cell 12, 1029–1041 (2003).

31. Rittinger, K. et al. Structural analysis of 14–3–3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14–3–3 in ligand binding. Mol. Cell 4, 153–166 (1999).

32. Wang, S. et al. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Mol. Cell 19, 461–473 (2005).

33. Gütter, T. et al. NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1. Nat. Struct. Mol. Biol. 17, 1367–1376 (2010).

34. Davies, A.A. et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol. Cell 7, 273–282 (2001).

35. Xu, D., Farmer, A., Collett, G., Grishin, N.V. & Chook, Y.M. Sequence and structural analyses of nuclear export signals in the NESdb database. Mol. Biol. Cell 23, 3677–3693 (2012).

36. Dong, X. et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 458, 1136–1141 (2009).

37. Mladenov, E., Anachkova, B. & Tsaneva, I. Sub-nuclear localization of Rad51 in response to DNA damage. Genes Cells 11, 513–524 (2006).

38. Gildemeister, O.S., Sage, J.M. & Knight, K.L. Cellular redistribution of Rad51 in response to DNA damage: a novel role for Rad51C. J. Biol. Chem. 284, 31945–31952 (2009).

39. Ciccia, A. & Elledge, S.J. The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179–204 (2010).

40. San Filippo, J., Sung, P. & Klein, H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 77, 229–257 (2008).

41. Dingwall, C. & Laskey, R.A. Protein import into the cell nucleus. Annu. Rev. Cell Biol. 2, 367–390 (1986).

42. Krogan, N.J. et al. Proteasome involvement in the repair of DNA double-strand breaks. Mol. Cell 16, 1027–1034 (2004).

43. Mannen, T., Andoh, T. & Tani, T. Dss1 associating with the proteasome functions in selective nuclear mRNA export in yeast. Biochem. Biophys. Res. Commun. 365, 664–671 (2008).

44. Gudmundsdottir, K., Lord, C.J., Witt, E., Tutt, A.N. & Ashworth, A. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep. 5, 989–993 (2004).

45. Saeki, H. et al. Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc. Natl. Acad. Sci. USA 103, 8768–8773 (2006).

46. Edwards, S.L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).

47. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116–1120 (2008).

48. Siuad, N. et al. Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains. PLoS Genet. 7, e1002409 (2011).

49. Kocij, M., Zhou, Q., Lisby, M. & Holloman, W.K. Brh2-Dss1 interplay enables properly controlled recombination in Ustilago maydis. Mol. Cell Biol. 25, 2547–2557 (2005).

50. Han, X., Saito, H., Miki, Y. & Nakashima, A.A. CRM1-mediated nuclear export signal governs cytosplasmic localization of BRCA2 and is essential for centrosomal localization of BRCA2. Oncogene 27, 2969–2977 (2008).

51. Honrado, E. et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J. Clin. Oncol. 23, 7503–7511 (2005).

52. Mifra, A. et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 55, 696–704 (2009).
**ONLINE METHODS**

**Antibodies and siRNAs.** The antibodies used in this work are listed in Table 1. The targeted mRNAs and the corresponding siRNA sequences used were BRCA2 (Dharmacon siGenome),

- GAAAGCCGAGUAGGUGUUAUUUA
- GCGACUCUGUCUGGACGAAUAC
- AAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAA

- GAAUUGUGUUGCAGAGCUU; (also used as single siRNA)

- Flag tag M2, F1804 Sigma WB and IF 1:3,000 (WB), 1:2,000 (IF)

- SC1 (rabbit polyclonal) Ab992 Abcam WB 1:2,000

| Antibody against | Catalog or clone number | Source | Application | Dilution | Comments |
|------------------|-------------------------|--------|-------------|----------|----------|
| RAD51            | 14B4                    | Genetex | WB         | 1:2,000  |          |
| RAD51            | B01P                    | Abnova  | IF         | 1:2,000  |          |
| RAD51            | Ab1                     | Calbiochem | IF         | 1:1,000  | Polyclonal serum (batches before 2010) |
| Flag tag         | M2, F1804               | Sigma   | WB and IF  | 1:3,000 (WB), 1:2,000 (IF) |
| DSS1 (goat polyclonal) | Ab5649             | Abcam   | WB and IF  | 1:1,000 (WB), 1:500 (IF) |
| GFP              | 632381                  | Clontech | WB         | 1:2,000  |          |
| GFP              | 632381                  | Clontech | IP         | 1 µL per mg of lysate | |
| SCC1 (rabbit polyclonal) | MBL-598          | MBL     | IF         | 1:1,000  |          |
| MEK2             | 610236                  | BD Transduction Laboratories | WB | 1:5,000 | Human MEK2 |
| BRCA2            | Ab1, OP95               | Merck   | WB         | 1:500    | Pan-species |
| BRCA2            | H-300                   | Santa Cruz | WB       | 1:500    | Pan-species |
| GST              | AB92                    | Abcam   | WB         | 1:5,000  |          |
| His tag          | 631212                  | Clontech | WB         | 1:5,000  |          |

WB, western blotting; IF, immunofluorescence; IP, immunoprecipitation.

*The proteins to which the antibodies are specific are listed.*
were reverse transfected with the indicated siRNAs at a final concentration of 100 nM Lipofectamine. Full-length BRCA2 was introduced into U2OS cells using the construct in standard DMEM plus 10% FBS with penicillin-streptomycin. Cell culture and transfection. MCF10A cells were grown in DMEM and F12 (1:1) with 15 mM HEPES (Invitrogen), 1× nonessential amino acids (Invitrogen), 1× glutamate-penicillin-streptomycin, medium (Sigma) supplemented with 15% FBS (Hyclone), 1 mM sodium pyruvate, and pyridoxine (Gibco) supplemented with 10% fetal calf serum (Gibco). To make the His-DSS1 construct, full-length DSS1 sequences were cloned into the vector NLS-sYFP-DBD construct and cloned into the Sall and NotI sites of the vector pGEX-4T3 (GE Healthcare). To make the GST-DDB construct for the in vitro binding assay, the BRCA2 DDB (from hsBRCA2 residues 2461–2975) was PCR amplified from the NLS-sYFP-DDB construct and cloned into the Sall and NotI sites of the vector pGEX-4T3 (GE Healthcare). For GST-DDB2D23H, the same region was PCR amplified from the NLS-sYFP-DDB2D23H construct. The primers used were forward, 5′-GGCGGGACCGGTCATCAATCAGGAGCGACTT-3′; reverse, 5′-GGCGGGACCGGTCATCAATCAGGAGCGACTT-3′.

To make the GST-DDB construct and GST-RAD51-SAM constructs, the respective RAD51 mutant sequences were PCR amplified from the GFP-RAD512D23H and GFP-RAD51-SAM constructs and cloned into the Sall and NotI sites of the vector pGEX-4T3 using the following primers:

forward, 5′-GGCGGACCGGTCATCAATCAGGAGCGACTT-3′; reverse, 5′-GGCGGACCGGTCATCAATCAGGAGCGACTT-3′.

To make the His-DSS1 construct, full-length DSS1 sequences were cloned into the NdeI and BamHI sites of a modified pET28a vector (Novagen).

The primers used were forward, 5′-GGCGGCATATGTCAGAGAAAAAGCAGC-3′; reverse, 5′-GGCGGCATATGTCAGAGAAAAAGCAGC-3′.

The CRM1 and Ran(Q66L) constructs for bacterial overexpression were gifts from D. Görlich53,54 (Max Planck Institute, Göttingen). BR4 cytokines were synthesized by Cambridge Research Biochemicals Ltd. with an N-terminal biotin moiety attached through a six–aminohexanoic acid spacer and a C-terminal amine. The peptide was kept KLETLFHTASGKVKIAKESLD KVKNLFDDEKQ.

**Cell culture and transfection.** 293T and U2OS cells were cultured in sterile filtered growth medium (DMEM with GlutaMAX-I, 1,450 mg l−1 β-galactosidase, sodium pyruvate and pyridoxine (Gibco) supplemented with 10% fetal calf serum (Gibco) and 2% penicillin-streptomycin (Gibco)) in a 37 °C humidified incubator in the presence of 5% CO2. Cells were split every 2–3 d and maintained at 50% confluency. MCFC10A cells were grown in DMEM and F12 (1:1) with 15 mM HEPES (Gibco) supplemented with 5% horse serum (Invitrogen), 10 μg ml−1 insulin (Sigma), 20 ng ml−1 epidermal growth factor (Sigma), 100 ng ml−1 histone (Sigma), 500 ng ml−1 hydrocortisone (Sigma) and 1% penicillin-streptomycin. ES cells were grown in gelatinized plates with Glasgow minimum essential medium (Sigma) supplemented with 15% FBS (Hyclone), 1 mM sodium pyruvate, 1× nonessential amino acids (Invitrogen), 1× glutamate-penicillin-streptomycin, (Invitrogen), 100 μM β-mercaptopetoxyethanol and 1,000 units ml−1 of a leukemia inhibitory factor (ESGO Chemicon).

**Transient transfection of DBD plasmids was performed by lipofection using Lipofectamine 2000 (Invitrogen) using 1 μg DNA and 3 μl Lipofectamine in OptiMEM (Invitrogen) for 10 cells. For high-content microscopy, U2OS cells were plated in a 24-well plate. 1 d after plating, cells were transfected with a NLS-syFP-DBD construct (either WT or the D2723H mutant; 0.25 μg) together with an empty mCherry plasmid or an mCherry-DSS1 plasmid (0.125 μg) using Lipofectamine. Full-length BRCA2 was introduced into U2OS cells using the Amoxa Cell Line Nucleofector Kit V and the Nucleofector I device with the program X-01 (Lonza). For high-content microscopy experiments, MCFC10A cells were reverse transfection with the indicated siRNAs at a final concentration of 25 nM using DharmaFECT 1 transfection reagent (Fermentas GmbH, Thermo Fisher Scientific) in a 96-well plate. EUFA232BRCA2 (EUFA-BRCA2343) cell lines were established by stably transfecting EUFA423 cells (SV40-immortalized BRCA2-deficient human fibroblasts) with the pCAG-Flag-BRCA2-ires-neo construct in standard DMEM plus 10% FBS with penicillin-streptomycin supplemented with 750 μg ml−1 G418.

**Cell viability assay.** Cells were plated into 96-well plates at a density of 8,000 cells per well. Different doses of MMC (Sigma) were added (four wells per dose per cell line), and the plates were incubated at 37 °C for five doubling times. CellTiter-Blue reagents (Promega) were added to each well of the 96-well plate according to the manufacturer’s guidelines. The plates were incubated at 37 °C for 1–2 h in a humidified 5% CO2 atmosphere. The number of viable cells was determined using the Fusion plate reader at an absorbance of 590 nm. A similar procedure was followed for the cell viability assay for ES cells exposed to different doses of ionizing radiation using a Faxitron X-ray unit.

**Lifetime measurements.** DBD- and DSS1-transfected cells were plated on MatTek poly-D-lysine–coated, 1 glass bottom 35-mm dishes, and the medium was replaced with phenol red–free L15. Experiments were performed on a TCSPC system (Becker and Hickl Inc., SPC 830) connected to the descanned and fiber-coupled output of an Olympus FV300 confocal scanner (Lasar Analytics Group, Department of Chemical Engineering). A supercontinuum laser (Fianium Inc., SC400) was used as the illumination source. An excitation wavelength of 436 ± 1 nm (range) was selected by an Acousto Optic Tunable Filter (AOTFInc VIS, AA Opto-Electronique, Orsay, France) and coupled into the confocal scanner. The fluorescence output was filtered between 480 and 550 nm before being detected by the TCSPC photomultiplier tube. TCSPC data were analyzed to generate lifetime information on dedicated Matlab (MathWorks, Inc.) and Becker and Hickl software.

**Immunofluorescence analyses.** Cell staining and immunofluorescence analyses were carried out as described previously55. Briefly, transfected and untransfected cells were grown on coverslips and subjected to different treatments as indicated in the text before fixation. Cells for IF experiments were grown on coverslips to 70–80% confluence, washed in PBS and fixed in 4% paraformaldehyde or 95% ethanol plus 5% acetic acid. The cells were permeabilized by adding Tris-buffered saline (TBS) with 0.1% Triton X-100 and 0.2% Tween (TBS-Triton-Tween) for 5 min, blocked in TBS-Triton-Tween plus 2% BSA and incubated with the indicated primary and secondary antibodies (Table 1) in a humidified chamber with TBS-Triton-Tween washes between the primary and secondary incubation. The coverslip was then mounted onto a slide for viewing using a mounting medium with DAPI. Immunofluorescence images were captured using a Zeiss Axiovert200 LSM510meta confocal microscope using a 40× objective with fixed optical slice, laser power and detector and amplifier settings for all samples across each individual experiment to allow for comparison.

**High-content microscopy for adherent cells.** High-content microscopy experiments were performed on the Cellomics VTI-Arrayscan Instrument (Thermo Fisher), as described previously56, in 96-well (Nunc) or 24-well plates. Transfections were performed using 0.25 μg or 0.125 μg of DNA and Lipofectamine. The cells were treated with specified DNA-damaging agents, fixed with 4% formaldehyde for 10 min, immunostained as per conventional protocols and incubated with 0.1% Triton X-100 with Hoechst 33,342 DNA dye for 10 min followed by PBS washes. Cellomics VTI ArrayScan was used for image acquisition using the Componental Analysis BioApplication and a 40× nonimmersion objective. Hoechst staining was used for object identification, and the average intensity of the fluorescent signal per nucleus was estimated using the target-activation Cellomics BioApplication. 300–500 cells were analyzed per well, and standard errors were calculated from an average of the means of multiple wells.

**Immunoprecipitation.** Whole-cell extracts were prepared from 15 × 106 293T cells 24 h after transfection. The trypticinized or scraped cells were spun down in a Beckman centrifuge at 1,000 r.p.m. for 3 min, washed once with PBS and resuspended in 1 ml of ice-cold immunoprecipitation lysis buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 0.5% NP-40, 10 mM EDTA, 2 mM β-glycerophosphate, 1 mM DTT and 1 mM PMSF supplemented with protease inhibitors (Roche)) for 15 min on ice. Extracts were then spun down in an Eppendorf centrifuge for 15 min at 12,000 r.p.m., and the supernatant was collected and quantified for protein concentration by the bicinchoninic acid assay (Sigma). 1 mg of whole-cell extract was preclared with 30 μl of a 50% slurry of protein A-Sepharose (Sigma) for 20 min at 4 °C with gentle shaking to reduce nonspecific protein-bead interactions followed by immunoprecipitation using 1–2 μg of antibody.
(specified in Table 1) and 30 µl of a 50% slurry of protein A-Sepharose overnight in a cold room with gentle shaking. The immune complexes were then washed four times in ice-cold immunoprecipitation lysis buffer and one time in PBS before resuspension in 4× buffer (Invitrogen) and 50 mM DTT.

**In vitro pulldown assays.** The in vitro CRM1 binding assays were performed using an assay described previously33. For each assay condition, 1 µg of GST-tagged protein (DBD, DBD D2723H, RAD51 F86E or RAD51-SAM) bound to glutathione–Sepharose 4B beads was incubated with 1 µM CRM1 and/or Ran-GTP, as indicated, for 1 h at 4 °C in 500 µl of binding buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM Mg(OAc)2, 5 mM DTT and 20 µM GTP-γS (a nonhydrolyzable GTP analog)). DSS1 proteins or BRCA4 peptides (or binding buffer alone for the GST control) were then added to individual tubes as indicated, followed by incubation at 4 °C for 2 h. Beads were washed three times with 500 µl of binding buffer, followed by elution of proteins and SDS-PAGE. DBD, DBD D2723H, RAD51 F86E and RAD51-SAM were detected by immunoblotting with antibody to GST (Table 1), and CRM1 was detected by immunoblotting with His-specific antibody (Table 1).

**Cell fractionation.** Cells were washed in PBS and resuspended in solution A (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT; protease and phosphatase inhibitors). Cells were incubated on ice for 5 min, and the cytoplasmic (S1) and nuclear (P1) fractions were harvested by centrifugation at 1,300 g for 10 min. The soluble nuclear (S3) and chromatin fractions were harvested by centrifugation at 1,300 g for 4 min. Isolated nuclei were then washed in solution A, lysed in solution B (0.1% Triton X-100, 3 mM EDTA, 0.2 mM EGTA, 10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, protease and phosphatase inhibitors) and incubated on ice for 5 min, and the cytoplasmic (S1) and nuclear (P1) fractions were harvested by centrifugation at 1,700 g for 10 min. The soluble nuclear (S3) and chromatin fractions were harvested by centrifugation at 1,300 g for 4 min. Isolated nuclei were then washed in solution A, lysed in solution B (0.1% Triton X-100, 3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease and phosphatase inhibitors) and incubated on ice for 10 min. The soluble nuclear (S3) and chromatin fractions were harvested by centrifugation at 1,700 g for 4 min. To release chromatin-bound proteins by nuclease treatment, the P2 fraction was incubated in solution A plus 1 mM CaCl2 and 5 U micrococcal nuclease for 15 min at 37 °C, after which the reaction was stopped by the addition of 1 mM EGTA and spun down at 10,000 g for 5 min. The supernatant was collected and the pellet was resuspended in 4× loading buffer (Invitrogen) and 50 mM DTT.

Proteins were resolved on 3–8% Tris-aceate SDS-PAGE (Invitrogen) for the BRCA2 experiments, 4–12% MES SDS-PAGE (Invitrogen) for most of the other experiments and 4–20% Tris-glycine gels for the DSS1 experiments. Transfer was performed to PVDF membranes (Immobilon-P, Millipore) at 30 V for 2 h. Western blots were blocked in 5% milk (Marvel) and 0.5% Tween-20 in TBS for 4 min. To release chromatin-bound proteins by nuclease treatment, the P2 fraction was incubated in solution A plus 1 mM CaCl2 and 5 U micrococcal nuclease for 15 min at 37 °C, after which the reaction was stopped by the addition of 1 mM EGTA and spun down at 10,000 g to collect the supernatant enriched for chromatin proteins (P3). The S3 and P3 fractions were pooled to obtain a nuclear extract.

**Quantitative RT-PCR.** To analyze the effects of siRNA knockdown, 0.5 µg of total RNA, which was extracted with the RNeasy Plus Mini Kit (Qiagen), was used for cDNA synthesis using the Cloned AMV First-Strand Synthesis kit (Invitrogen). Quantitative RT-PCR was performed using the LightCycler 480 SYBR Green 1 Master mix (Roche) with the following primers:

- GAPDH forward, GCCTATCGTGTTGCGAGAC; reverse, TGGCTCC TTTGGGATGATGGA;
- ATR forward, TCCCTTGAATACAGTGGCCTA; reverse, TCCCTTGA AAGTACGGCAGATTC;
- DSS1 forward, GAAAAGCAGCGGGTAGACTT; reverse, ATCCCAAT TATCCCTCCAGACA;
- BRCA2 forward, TGGCTGATGTTAGTGAGTCCTA; reverse, TTGGAGA TCCACACCTGGAGTGTCA.

RNA was made from exponentially growing ES cells using a Qiagen total RNA kit. 2 µg RNA was converted into cDNA using the Roche Transcriptor High Fidelity cDNA Synthesis Kit, and quantitative RT-PCR was performed as described above. The Ct values were directly represented in the figure to provide an unbiased assessment, and GAPDH was used as a control.

The original images of the blots presented in this study are shown in Supplementary Figure 8.

53. Hattori, H., Skoulidis, F., Russell, P. & Venkitaraman, A.R. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. Mol. Cancer Ther. 10, 670–678 (2011).
54. Jayasekharan, A.D. et al. DNA damage regulates the mobility of Brca2 within the nucleoplasm of living cells. Proc. Natl. Acad. Sci. USA 107, 21937–21942 (2010).
55. Frey, S., Richter, R.P. & Gorlich, D. Fg-rich repeats of nuclear pore proteins form a three-dimensional meshwork with hydrogel-like properties. Science 314, 815–817 (2006).
56. Ayoub, N., Jayasekharan, A.D., Bernal, J.A. & Venkitaraman, A.R. HP1-β mobilization promotes chromatin changes that initiate the DNA damage response. Nature 453, 682–686 (2008).